78706-26-0

Basic information

• Product Name: 5,7-DICHLORO-[1,2,4]TRIAZOLO[1,5-A]PYRIMIDINE
• Synonyms: 5,7-DICHLORO-[1,2,4]TRIAZOLO[1,5-A]PYRIMIDINE;5,7-DICHLORO-[1,2,4]TRIAZOLO[1,5-A]PYRIMIDINE(WXG02934)
• CAS NO: 78706-26-0
• Molecular Formula: C₅H₂Cl₂N₄
• Molecular Weight: 189
• Product Categories: Heterocycles, Miscellaneous Reagents
• Mol File: 78706-26-0.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 5,7-DICHLORO-[1,2,4]TRIAZOLO[1,5-A]PYRIMIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 5,7-DICHLORO-[1,2,4]TRIAZOLO[1,5-A]PYRIMIDINE(78706-26-0)
• EPA Substance Registry System: 5,7-DICHLORO-[1,2,4]TRIAZOLO[1,5-A]PYRIMIDINE(78706-26-0)

Safety Data

• Hazardous Substances Data: 78706-26-0(Hazardous Substances Data)

Usage

Description

5,7-DICHLORO-[1,2,4]TRIAZOLO[1,5-A]PYRIMIDINE is a chemical compound belonging to the triazolopyrimidine class. It is characterized by the presence of two chlorine atoms at the 5th and 7th positions, which contribute to its unique properties and potential applications in various fields.

Uses

Used in Pharmaceutical Industry:
5,7-DICHLORO-[1,2,4]TRIAZOLO[1,5-A]PYRIMIDINE is used as a key intermediate in the synthesis of triazolopyrimidine inhibitors. These inhibitors exhibit potent antimalarial activity, making them valuable in the development of new drugs to combat malaria, a disease that affects millions of people worldwide.
In the synthesis process, 5,7-DICHLORO-[1,2,4]TRIAZOLO[1,5-A]PYRIMIDINE serves as a building block for the creation of more complex molecules with enhanced biological activity. 5,7-DICHLORO-[1,2,4]TRIAZOLO[1,5-A]PYRIMIDINE's structural features, particularly the presence of the chlorine atoms, allow for further chemical modifications and functionalization, enabling the development of more effective antimalarial agents.
The use of 5,7-DICHLORO-[1,2,4]TRIAZOLO[1,5-A]PYRIMIDINE in the pharmaceutical industry highlights its potential as a versatile and valuable compound in the ongoing fight against malaria. Its unique properties and reactivity make it an attractive candidate for further research and development, with the ultimate goal of improving global health and reducing the burden of this devastating disease.

Upstream product

• 40775-75-5 [1,2,4]triazolo[1,5-a]pyrimidine-5,7-diol 
• 61-82-5 3-amino-1,2,4-triazole 
• 105-53-3 diethyl malonate 

Downstream Products

• 134790-89-9 (5-Chloro-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)-(2-nitro-phenyl)-amine 
• 808733-71-3 (5-chloro-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)-(4-methanesulfonyl-phenyl)-amine 
• 808734-39-6 (4-benzenesulfonyl-phenyl)-(5-chloro-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)-amine 
• 134791-18-7 5-{N'-[1-Phenyl-meth-(E)-ylidene]-hydrazino}-[1,2,4]triazolo[1,5-a]pyrimidin-7-ol 
• 134791-23-4 5-{N'-[(E)-3-Phenyl-prop-2-en-(E)-ylidene]-hydrazino}-[1,2,4]triazolo[1,5-a]pyrimidin-7-ol 
• 134791-19-8 5-{N'-[1-(4-Methoxy-phenyl)-meth-(E)-ylidene]-hydrazino}-[1,2,4]triazolo[1,5-a]pyrimidin-7-ol 
• 134791-24-5 N-[1-Phenyl-meth-(E)-ylidene]-N'-(7-pyrrolidin-1-yl-[1,2,4]triazolo[1,5-a]pyrimidin-5-yl)-hydrazine 
• 134791-22-3 5-{N'-[1-(2,4-Dichloro-phenyl)-meth-(E)-ylidene]-hydrazino}-[1,2,4]triazolo[1,5-a]pyrimidin-7-ol 
• 134791-21-2 5-{N'-[1-(2-Nitro-phenyl)-meth-(E)-ylidene]-hydrazino}-[1,2,4]triazolo[1,5-a]pyrimidin-7-ol 
• 134791-20-1 5-{N'-[1-(4-Nitro-phenyl)-meth-(E)-ylidene]-hydrazino}-[1,2,4]triazolo[1,5-a]pyrimidin-7-ol 
• 134791-25-6 N-[(E)-3-Phenyl-prop-2-en-(E)-ylidene]-N'-(7-pyrrolidin-1-yl-[1,2,4]triazolo[1,5-a]pyrimidin-5-yl)-hydrazine 
• 134791-35-8 C₁₂H₁₂N₆O₃S 
• 134791-28-9 N-[1-(2,4-Dichloro-phenyl)-meth-(E)-ylidene]-N'-(7-pyrrolidin-1-yl-[1,2,4]triazolo[1,5-a]pyrimidin-5-yl)-hydrazine 

Relevant articles and documents

BCL6-targeting aromatic ring five-membered aromatic heterocyclic micromolecular organic compound and derivative and application thereof

The invention discloses an aromatic ring five-membered aromatic heterocyclic micromolecular organic compound or related analogues or pharmaceutically acceptable salts thereof. The structures of the compound are shown as formulas (I-IX). The invention also

The identification of GPR3 inverse agonist AF64394; The first small molecule inhibitor of GPR3 receptor function

The identification of the novel and selective GPR3 inverse agonist AF64394, the first small molecule inhibitor of GPR3 receptor function, is described. Structure activity relationships and syntheses based around AF64394 are reported.

Pyrazolo[1,5-a]pyrimidines, triazolo[1,5-a]pyrimidines and their tricyclic derivatives as corticotropin-releasing factor 1 (CRF1) receptor antagonists

To identify structurally novel CRF1 receptor antagonists, a series of bicyclic core antagonists, pyrazolo[1,5-a]pyrimidines, triazolo[1,5-a] pyrimidines, imidazo[1,2-a]pyrimidines and pyrazolo[1,5-a][1,3,5]triazines were designed, synthesized and evaluated as CRF1 receptor antagonists. Compounds 2-27 showed binding affinity (IC50 = 4.2-418 nM) and antagonist activity (EC50 = 4.0-889 nM). Compound 5 was found to show oral efficacy in an Elevated Plus Maze test in rats. Further chemical modification of them led us to discovery of the tricyclic core antagonists pyrazolo[1,5-a]pyrrolo[3,2-e] pyrimidines. The discovery process of these compounds is presented, as is the study of the structure-activity relationship.